Commission Makes Sanofi Commitments Legally Binding to Settle Flu Vaccine Antitrust Probe

The European Commission has made legally binding a set of commitments offered by pharmaceutical company Sanofi to resolve preliminary EU antitrust concerns. Regulators had investigated allegations that Sanofi carried out disparagement campaigns in Germany and France against Fluad, an enhanced flu vaccine produced for vulnerable patients. Fluad is the only enhanced flu vaccine on the market competing directly with Sanofi’s own product, Efluelda. Following the Commission's preliminary findings of potential anticompetitive behavior, Sanofi submitted commitments to address the regulatory concerns, which the Commission has now accepted and rendered legally enforceable.

For vulnerable patients and public health authorities, competitive vaccine markets are essential to ensuring choice and maintaining healthcare options. Enhanced flu shots are specifically tailored for high-risk groups who require stronger protection during seasonal outbreaks. If a company uses disparagement tactics to unfairly cast doubt on its sole competitor, medical providers may be discouraged from adopting alternative vaccines, potentially narrowing treatment options for patients. By binding Sanofi to its commitments, European competition authorities aim to protect fair market rivalry so that medical choices in Germany and France remain guided by clinical evidence rather than aggressive marketing campaigns.

In the EU regulatory toolkit, a commitment decision allows the Commission to clean up market behavior without enduring years of formal litigation over an infringement finding. Under EU competition rules, when officials flag preliminary antitrust concerns, the company under fire can propose remedies. If the Commission accepts them, these promises become legally binding: the investigation ends, no fine is immediately imposed, and the company avoids a formal finding of breach, provided it follows through. It is the administrative world’s version of a binding resolution—allowing regulators to adjust market dynamics promptly while keeping corporate legal departments from occupying the EU courts for a decade.

Sanofi must now abide by the commitments it offered to the Commission across the affected German and French markets. The European Commission will oversee compliance with these legally binding terms. If Sanofi breaches its promises, the executive retains the power to impose fines of up to 10 percent of the company’s worldwide annual turnover without having to prove an antitrust breach from scratch.